Calviri, Inc., a company spun out of Arizona State University and based in the Phoenix Bioscience Core, has announced the successful conclusion of the Vaccine Against Canine Cancer Study on May 4, a five-year clinical trial investigating a novel preventive cancer vaccine in dogs. This multi-centre, double-blind, placebo-controlled study, the largest of its kind in veterinary oncology, represents a significant milestone in the fight against canine cancer, the company said in a press release. Attempts...